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In this study we exa mined the effects of intradermal injec-
tions of human co mplem ent split prod uct C 5a in 10 patients 
w ith psoriasis in long-term trea tment with methotrexa te 
(MTX). T he C 5a was inj ected at the end of the weekly 
MTX cycle just before the intake of the first MTX dose 
and 3 h after the second of the 3 doses. T he C5a-indu ced 
ski n response was evalu ated by measuring the diameter of 
the w heal and the area of the fl are and by erythema index 
(EI), whi ch was determined objectively by reflectance spec-
trophotometry. In all patients the skin response was sig-
nifi cantly depressed when C5a was inj ected after MTX 
intake. The decrease of w heal, flare, and EI averaged 61. 6%, 
71.1 % , and 57.5%, respectively, w hen all parameters were 
obtained at maximal skin response. T he in vit ro chemotax is 
A typ ica l and characteri stic findin g in pso riasis is an epidcrmal infiltrate composed of 'neutrophil s and mononuclea r cells [1] . Accordingly, attention has been paid to the phcnomenon of Icuk ocy te mi gration to-ward the ho rn y layer [2-4]. It has been suggested 
that the prescncc of ncutrophils and mon on uclear cclls in the 
les ional psoriati c sk in is a result of an increased susccptibility of 
circulatin g Icuk ocy tes to chemoattra ctants [5 ,6] and of an in-
crcased amount of chemotactic fa cto rs produced in psoriati c epi-
dermis [7- 9]. 
Amon g the chemotacti c fac tors fo und in psoriati c epidermis 
arc peptides deri ved from thc fifth component of complement 
(C5) 19-111 Highly puri fied human C5a is a potent chemoat-
tractant fo r bo th neutrop hil s and monocytes [1 2]. Although C5a 
is rapidl y converted to the less po tent C5adcs-acgininc (C5adcmg) form 
by serum carboxy peptidase N, C5adcsacg demonstra tes man y bi-
ologic properties of the nati ve anaph ylatoxin , includi ng leukocyte 
chemotactic ac tivity [1 2]. Besides being a strong act iva tor o f leu-
kocyte chcmotaxis, C5a mediates scveral inAammatory rcsponses 
such as increased vascular permea bility [1 3], modulati on of Fc 
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of peripheral blood neutrophils and monocytes from the 
patients toward C 5a was markedly inhibited after intake 
of MTX (p < 0.01). The skin biopsies obtained after C5a 
inj ection before intake of MTX revealed a perivascular in-
fl ammatory infiltrate and considerable dennal edema. After 
MTX intake the number of infiltrating leukocytes and the 
degree of dermal edema was Inarkedly reduced . This study 
indica tes that MTX is a potent inhibitor of C 5a-induced 
skin infl am mation, and that this inhibition m ay be caused 
by a direct effect on circulating neutrophils and monocytes. 
T he results ob tai ned in this work support the idea that anti-
inflammatory effects of MTX may be partially responsible 
for its anti psoriatic effect. J In vest Dermato! 89: 192-196, 
'/ 987 
and C R 3 receptor ex press ion [14] , release of histamine from mast 
cell s [15]. augmentation of interleukin-l production by mono-
cytcs [1 6], and synthesis of leuko trienes by neutrophils [1 7]. 
Mcthotrexa te (MTX) is a drug that is extremely effective for 
the contro l of severe, w idesprcad , and di sa blin g psoriasis. T he 
exact modc of action is not fully understood. Recently, it has 
been shown that MTX ca uses a profound inhibition of neutrophil 
and monocy te chem otaxis [1 8, 19]. 
Because C5a may play an important ro le in the path ogenesis 
of the psori ati c lesions , and because almost all the data concerning 
the biologic ac tivities of human C5a have been generated in vitro 
or in animal studies, we have studied C5a-induced skin response 
in psoriatic patients before and after MTX intake. 
PATIE NTS AND METHODS 
Patients Ten patients (3 men and 7 women) on a long-term 
MTX maintenance regime were studied. T heir ages ran ged from 
24-72 years with a mean of 33 years. Mean duration of MTX 
therapy was 1.5 years rangin g from 3 months to 4 years. The 
MTX was given ora ll y every week in 3 di vided doses at 12-h 
intervals. The total weekly dose was 15 m g (5 m g + 5 m g + 5 
m g) . N one of the patients had used any adjun ct therapy for so me 
m onths. All patients had imp roved durin g MTX th erapy . At the 
time of in ves ti gation , all the patients were clinically in a stationary 
phase of the disease with 5-25% of sk in affected. Furthermore, 
there was no evidence that exten t of psoriasis correlated w ith 
cutaneous responsiveness to human C5a. All experiments (C5a 
inj ections, biopsies , and in vitro chemotaxis) wcre perfo rm ed at 
th e end of the MTX cycle just before the intake of the first MTX 
dose, and 3 h after the second of the 3 doses [20]. The leukocyte 
counts were obtained in all patients both before and 3 h after the 
in take of the second dose of MTX. All values were w ithin normal 
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range. However, a slight and nonsignificant decrease o fl eukocyte 
counts was no ti ced after MTX intake. 
Control Subjects T wenty-fi ve health y indi viduals (17 men and 
8 wo men) were in ves tiga ted fo r monocy te and neutrophil che-
motax is simultaneously w ith the patients. Their ages ranged fro l11 
17-48 yea rs w ith a m ea n o f 30 yea rs. 
Preparation of CSa Purifi ed CSa was prepared accordin g to 
the method of Fern and ez and Hugli [21 J, as described ea rlier [22], 
w ith th e modifi ca tion th at DL-2-mercapto meth yl-3-guanidino-
eth ylthiopropanoic acid (1 0 - 6 M) (Ca lbiochem Gmbh , Frankfurt, 
F.R. G.) was used instead of E-aminoca proic acid as serum car-
boxypeptidase N inhibito r. Anal ysis o f CSa perfo rm ed by sodium 
dodecy l sul fate-polyacrylamide gel electrophoresis accordin g to 
the method of Laemmli [23] revealed that the purifi ed human 
CSa mi grated as a single 15 kD band developed w ith Coomass ie 
blue. CSa was quantitated by radioimmunoassay (Upj ohn D i-
agnostic, Kalamazoo, Michigan). Dilutions of a CSa poo l were 
used fo r intraderm al inj ections as fo r in vitro determ ination o f 
leukocyte chemotax is. 
Skin Testing Intradermal skin tes t was perfo rm ed on the volar 
fo rearm of all 10 pso riatic patients using 1.0-1111 syringes (Pharma-
Plas t, Denmark) with 27-ga uge needles. The CSa in sterile sa line 
was injected at a concentration o f 340 ng/ml. Previous experi-
ments using different CSa concentrations had shown that inj ec-
tions of thi s concentration produ ced a considerable and well-
demarcated w hea l and fl are reaction in all tes ted indi viduals (Fig 
1). The injection volume was 100 ILl. The CSa w as inj ected at 
the end of the MT X cycle (6 days after the las t dose) and 3 h 
after the second dose in the same fo rea rm but not at the sa me 
site [20]. The CSa-induced skin response was evaluated by using 
3 para meters: (1) the diameter of w hea l, (2) the area of fl are, and 
(3) the deg ree of erythema (erythema index) . T he degree of er-
ythema was determined objectively using skin refl ectan ce spec-
trophotometer as described by D awson et al [24] and modified 
by Bj errin g and Andersen [2 51 . The measurements were per-
fo rm ed by illuminatin g the skin sur face by a high-press ure xenon 
short lamp (O sram X B O 150). The refl ected li ght from the skin 
was collected and guided through a Jobil1.-YvO l1. 20 UV mono-
chro mator, 1200 lines/mm. Intensity of the refl ected light in the 
ra nge of 350-680 nm was analyzed acco rdin g to the main ab-
so rbing area of oxygenized hemoglobin , and the erythema index 
(EI) was ca lculated accordin g to th e fo rmul a: 
EI = 100 x 10 -- x -- + 10 --( 1 (1 1 ) g R (S60) + 1. 5 log R(S40) g R(S7S) 
- 2.0 x (lOg R (~1 0) + log R (~1 0) )). 
R represents the spectral reflectance of the skin and the subscripts 
indi ca te the wavelength in nano meters [24] . 
Skin Biopsies Three-millimeter punch biopsies of skin were 
obtained fro m 4 patients after intradermal testing w ith CSa. T he 
biopsies of tes t sites were obtained 30 min after intradermal in-
jecti on. C hloraeth yl spray was used fo r local anesthesia. 
Cell Preparation M onocy tes and neutrophils from the patients 
and control individuals were prepared as described e~[lie[ [26,271. 
T he fin al cell preparation contained 92% monocytes (range 86- 97%) 
j ud ged by nonspecific esterase staining, and 111 0 re than 94% neu-
trophils judged by morphologic criteria . The viability of the cells 
was g rea ter than 97% as assessed by try pan blue exclusion. 
Leukocyte Chemotactic Assay T he chromium-51 assay has 
been described in detail ea rlier [26]. Briefl y, a blind well type o f 
chemotax is chamber was used (Nuclepore C orp. , Pleasanton , 
Califo rnia). A double membrane sys tem separated the cell com-
partm ent from the chemoattractant. An upper futer with pore 
size 2.0 ILm and 5.0 ILm was used for neutrophils and monocy tes, 
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Figure 1. Skin reaction 10 m in after the intra dermal injection of 34 ng 
of CSa. N o Rare and w heal reacti vi ty was ap parent at contro l injection 
site tested w ith 100 J..LI of sa line. 
respectively. T he lower fil ter had a pore size of 0. 45 1L I11 for bo th 
cell types. P urified human CSa was used as chemoattrac tant at a 
concentrati on of 5 x 1 0 - ~ M and 2.5 X 10 - 8 M for neutropbil s 
and monocy tes, res pectively. Previous expq iI11 ents had shown 
th at these concentratiO!lS are optimal fo r neutrophils and mono-
cytes bo th fro m hea lth y subj ects and fro m psoriatic patients. M e-
dium RPM! 1640 w ithout chemoa ttrac tant served as a control to 
meas ure rand om mig ration of the cell s. After incu bati on fo r 30 · 
m.in at 37°C the radioacti vity of each filter was de termined in a 
ga mma counter (LKB Wallac, T urku , Finland). T he chemotacti c 
ac tivi ty was expressed as a chemotactic index (CI), being the ra tio 
of acti ve migration in the presence of CSa to rando m mig rati on 
in th e presence o f medium alone. 
Statistics Statisti cal signi fica nce was assessed by using Wilcox-
on's test fo r pair di ffe rences. A p va lue below 0.05 was considered 
signifi cant. 
RES U LTS 
All patients tes ted intradermall y wi th CSa developed immedi ate 
wheal and fl are reactions (Fig 1). T he intensity of the CSa-induced 
inflammation was time related. In all patients the maxi mal w hea l 
and fl are was observed 4 min ± 0. 5 (mean ± SD) after CSa 
injecti on and the reaction resolved w ithin 1 h. T he sk in response 
was signifi cantl y depressed w hen C Sa was inj ected after MTX 
intake, i.e., 3 h after th e second dose ofM TX. [n the same patients 
the max imal w heal and fl are occurred at the same time bo th w hen 
CSa was injected before MTX in take and 3 h after th e second 
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Figure 2. Diameter of wheal (A) and area of flare (B) in 10 psoriatic 
patients tested intradermally with 34 ng of C5a. The test was performed 
before intake of the first dose of MTX and 3 h after the second of3 doses . 
The parameters are shown at maximal values, i.e., 4 min after C5a in-
jection, 
dose. Only the degree of the reaction was different. Figure 2 
shows the diameter of the wheal and the area of the flare before 
and after MTX intake obtained at optimal response, i.e., 4 min 
after C5a injection, The decrease of wheal and flare averaged 
61.6% ± 6.4 and 71.1 % ± 8,8, respectively (p < 0.01). 
The EI measured by reflectance spectrophotometry after C5a 
injection is shown in Fig 3. The maximal EI occurred after 10 
min both before and after MTX intake. After 50-60 min the EI 
returned to normal. At all time points the measured EI was sig-
nificantly decreased after MTX intake, and at 10 min (maximal 
response) the decrease was 57.5% ± 7.2 (mean ± SEM), 
The chemotactic activity of circulating monocytes and neutro-
phils from the patients with psoriasis toward C5a is demonstrated 
in Fig 4. The CI of monocytes was CI = 2.77 ± 0.16 (mean ± 
SEM) before MTX intake and CI = 1.66 ± 0.12 after intake of 
MTX (p < 0.01), which was below the 95% confidence limits 
of healthy controls. The chemotactic responsiveness of neutro-
phils before and after MTX intake was depressed in a similar way; 
from CI = 2.68 ± 0.11 to CI = 1.82 ± 0.09 (p < 0.01); however, 
this value was within the normal range , Only active migration 
toward C5a was inhibited by MTX. The random migration of 
the cells was unaffected. 
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Figure 3. Mean EI of 10 psoriatic patients tested intradermally with 34 
ng ofC5a . The test was performed before intake of the first dose ofMTX 
and 3 h after the second dose. The results are expressed as percent of EI 
before C5a injection. 
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Figure 4. Monocyte and neutrophil chemotaxis in vitro in 10 psoriatic 
patients. The investigation was performed before intake of the first MTX 
dose and 3 h after the second dose. CI = chemotactic index (see PatieJlts 
arid Methods). The shaded areas indicate 95% confidence limits of25 control 
subjects . 
The skin biopsies obtained 30 min after C5a injection before 
intake of MTX revealed a moderate perivascular infiltrate of neU-
trophils, mononuclear cells and eosinophils, marked dermal edema, 
and swelling of endothelial cells with strands of fibrin within and 
around their walls. The nuclear dust (leukocytoclasis) was also 
present (Fig 5) . The histologic pattern observed when C5a was 
injected after MTX intake consisted of none or mild perivascular 
infiltrate, the degree of dermal edema was clearly reduced, and 
there were only minimal vascular changes in the dermis (Fig 6) . 
DISCUSSION 
In the present study we have demonstrated that MTX is a potent 
inhibitor of C5a-induced skin response in patients with psoriasis. 
This was assessed not only by subjective measurements of wheal 
and flare but also by an objective determination of intensity of 
erythema produced by C5a. Biopsies from skin tests after the 
intake of MTX revealed less intense reaction; the number of in-
fi ltrating leukocytes was especially reduced in comparison with 
the reaction observed before the MTX was given. This should 
be seen in the light of the fact that penetration of neutrophils and 
mononuclear cells into epidermis is an early event in the patho-
genesis of psoriasis, 
Recently , it has been demonstrated that patients with active 
psoriasis have enhanced leukocyte chemotaxis [5,6]. Furthermore, 
chemotactic activity of neutrophils and monocytes corr~lated pos-
itively with the severity of psoriatic lesion, and the increase of 
neutrophil chemotaxis preceded exacerbation of psoriasis [28]. 
Drugs that inhibit leukocyte chemotaxis, like benoxaprofen and 
MTX, have a beneficial effect in psoriasis [19,29]. Methotrexate 
caused a 50-60% inhibition of the hyperactive neutrophil and 
monocyte chemotactic activity toward F-Meth-Leu-Phe (N-for-
myl-methionyl-leucyl-phenylalanine) within the first 48 h after 
intake [18,19] . Our patients were in long- term treatment with 
MTX. Their psoriasis was in a stable phase with a minimal skin 
affection. Accordingly, the chemotactic index ofleukocytes from 
the patients was within the normal values (Fig 4) . Nevertheless, 
a profound depression of monocyte and neutrophil chemotaxis 
was noticed after the second of 3 doses of MTX. Random mi-
gration was unaffected , suggesting that MTX interferes with 
cytoskeletal elements of the cell, which control direction of the 
movement. Thus our observations suggest a direct effect of MTX 
on circulating blood leukocytes. This idea is supported by van 
der Kerkhof and colleagues [20], who reported that MTX sup-
presses leukotriene B4 (L TB4)-induced infiltration of neutrophils 
into epidermis. Furthermore, patients neutropenic from bone 
marrow failure manifested reduced wheal and flare reactions and 
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Figure 5. Ski n biopsy obtained 30 min after the 
intraderm al injection of C5a . T he biopsy was per-
fo rmed before intake of the first dose of MTX . 
sparse to absent inflammatory infiltrates after intradermal injec-
tions of CSa (30J. 
It is interestin g that maximal wheal and flare reaction was ob-
served 4 min after CSa injection, whereas the maximal E I was 
measured 10 min after CSa injecti on, w hen w heal began to re-
solve. Since E I is a parameter for th e intensity of ery thema, this 
finding could be explained by relative paleness of cutaneous edem a, 
which is characteristic for wheal reaction. 
After CSa injection the microscopic changes were characteri zed 
by inflammatory infi ltrate, endothelial changes, and leukocyto-
clasis. In all cases the clinical reaction was transien t in nature. T he 
perivascular infiltrate observed after intradermal injection of CSa 
was no t so intense as described by Yancey and associates (311 . 
This difference ma y be explained by the fact that the authors 
mjected CSa in health y individuals, whereas we injected CSa in 
psoriatic patients in long-term MTX treatment. C linica ll y, how-
Figure 6. Skin biopsy obtained 30 min after the 
intradermal injection of C5a. The biopsy was per-
fo rmed 3 h after the second of 3 doses of MTX. 
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ever, th e size of wheal and fl are induced by 20 ng of CSa in their 
study co uld be compared w ith the reaction produced in our pa-
tients by using 34 ng of CSa. 
Electron microscopy studies have documented mast cell de-
granul at ion w ithin 3 min ofCSa injection 131 ], an d it is of interest 
that mast cell-depleted no rm al sk in eli cited d imini shed or 11 0 re-
action after CSa injection 1" 30], Accordingly, the impairment of 
CSa-induced reaction in th e human skin ca used by MTX may be 
re lated to an effect on mast cells. It cannot be excluded that the 
target of the MTX effect on cutaneolls reactivity is the cells res-
ident in the skin. 
The mechan ism by which MTX inhibits CSa-induced skin re-
sponse is unknown. H owever, from our stud y it appears that the 
antipsoriati c effect of MTX is not limited to the inhibition of 
epidermal cell proliferation [32], but al so implies a direct effect 
on peripheral blood leukocytes as demonstrated by in vitro che-
196 T ERN OW ITZ ET AL 
motac ti c studies and biopsies from skin tes t after intraderm al 
inj ection of C 5a. 
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